Mydrane

Lidocaine Hydrochloride, the active ingredient in Mydrane, is a combination ophthalmic agent presented as an intracameral solution for intraocular use. It provides rapid local anesthesia and facilitates pupil dilation during ophthalmic surgery.\n\nGNH India supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mydrane is used in ophthalmic procedures that require both anesthesia and pupil dilation.\n\nCataract surgery: provides effective pupil dilation and intraocular anesthesia to enable safe lens removal.\nIntraocular surgery (e.g., vitrectomy): facilitates mydriasis and analgesia for better surgical access.\nOther ophthalmic procedures: supports surgical exposure by dilating the pupil and delivering local anesthesia.

Mydrane may cause a range of ocular and systemic reactions.\n\nCommon Side Effects:\n- Ocular discomfort or burning sensation\n- Transient increase in intra‑ocular pressure\n- Mild conjunctival hyperemia\n- Temporary blurred vision\n- Mild corneal edema\n- Light‑headedness or mild headache\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (anaphylaxis)\n- Persistent mydriasis lasting >24 hours\n- Sustained intra‑ocular pressure elevation\n- Corneal ulceration or keratitis\n- Endophthalmitis\n- Retinal toxicity

Before using Mydrane, clinicians should consider several safety measures.\n\nPatient assessment: evaluate ocular health and allergy history.\nContraindications: avoid in patients with known hypersensitivity to lidocaine, phenylephrine, or tropicamide.\nIntra‑ocular pressure monitoring: check IOP before and after administration.\nCardiovascular caution: phenylephrine may raise systemic blood pressure; monitor hypertensive patients.\nPregnancy and lactation: limited data; use only if benefit outweighs risk.\nStore at ambient temperature: keep in original container, protect from light and moisture.

Mydrane can interact with other medications that affect ocular or systemic physiology.\n\nMajor Interactions (Avoid):\n- Systemic alpha‑agonists (e.g., phenylephrine nasal spray) may cause additive hypertensive effects.\n- Monoamine oxidase inhibitors can potentiate phenylephrine‑induced blood pressure rise.\n- Concurrent use of other local anesthetics may increase risk of toxicity.\n\nModerate Interactions (Monitor Closely):\n- Topical non‑steroidal anti‑inflammatory drugs may delay corneal healing.\n- Systemic antihypertensives may blunt phenylephrine‑mediated pupil dilation.